000153167 001__ 153167
000153167 005__ 20240229123040.0
000153167 0247_ $$2doi$$a10.1002/ijc.32868
000153167 0247_ $$2pmid$$apmid:31943160
000153167 0247_ $$2ISSN$$a0020-7136
000153167 0247_ $$2ISSN$$a1097-0215
000153167 037__ $$aDKFZ-2020-00220
000153167 041__ $$aeng
000153167 082__ $$a610
000153167 1001_ $$0P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aAmitay, Efrat$$b0$$eFirst author$$udkfz
000153167 245__ $$aPostmenopausal hormone replacement therapy and colorectal cancer risk by molecular subtypes and pathways.
000153167 260__ $$aBognor Regis$$bWiley-Liss$$c2020
000153167 3367_ $$2DRIVER$$aarticle
000153167 3367_ $$2DataCite$$aOutput Types/Journal article
000153167 3367_ $$0PUB:(DE-HGF)16$$2PUB:(DE-HGF)$$aJournal Article$$bjournal$$mjournal$$s1608114014_20752
000153167 3367_ $$2BibTeX$$aARTICLE
000153167 3367_ $$2ORCID$$aJOURNAL_ARTICLE
000153167 3367_ $$00$$2EndNote$$aJournal Article
000153167 500__ $$a2020 Aug 15;147(4):1018-1026#EA:C070#LA:C070#
000153167 520__ $$aPostmenopausal hormone replacement therapy (HRT) was found to be associated with lower risk of colorectal cancer (CRC). However, little is known regarding associations with molecular subtypes of CRC. The current study includes female participants of a large German population-based case-control study (922 CRC cases and 1,183 controls). Tumor tissue samples were analyzed for microsatellite instability (MSI), CpG island methylator phenotype (CIMP), BRAF and KRAS mutation status. Multivariable logistic regression models were used to assess the association of HRT use with molecular subtypes and pathways. Postmenopausal HRT use was overall associated with reduced risk of CRC (adjusted odds-ratio (aOR) 0.62, 95% confidence interval (CI) 0.50-0.76) and no major differences were observed for molecular subtypes or for tumor marker combinations representing molecular pathways. When stratified by median age (≤/>71 years) potentially stronger risk reductions were observed in the older group for subtypes showing MSI (OR = 0.36, 95%CI 0.17-0.76), BRAF mutation (OR = 0.40, 95%CI 0.30-0.83) and CIMP-high (OR = 0.40, 95%CI 0.21-0.73) and for CRC suggestive of the sessile serrated pathway (OR = 0.45, 95%CI 0.20-1.01). In conclusion, postmenopausal use of HRT was similarly associated with risk reduction of major molecular tumor subtypes and pathways of CRC. Potentially stronger risk reductions with CRC subtypes diagnosed at higher ages require confirmation and clarification from other studies. The current study extends the limited understanding of the mechanisms of HRT in CRC prevention. This article is protected by copyright. All rights reserved.
000153167 536__ $$0G:(DE-HGF)POF3-313$$a313 - Cancer risk factors and prevention (POF3-313)$$cPOF3-313$$fPOF III$$x0
000153167 588__ $$aDataset connected to CrossRef, PubMed,
000153167 7001_ $$0P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aCarr, Prudence R$$b1$$udkfz
000153167 7001_ $$0P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aJansen, Lina$$b2$$udkfz
000153167 7001_ $$0P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aAlwers, Elizabeth$$b3$$udkfz
000153167 7001_ $$aRoth, Wilfried$$b4
000153167 7001_ $$aHerpel, Esther$$b5
000153167 7001_ $$aKloor, Matthias$$b6
000153167 7001_ $$aBläker, Hendrik$$b7
000153167 7001_ $$0P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aChang-Claude, Jenny$$b8$$udkfz
000153167 7001_ $$0P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aBrenner, Hermann$$b9$$udkfz
000153167 7001_ $$0P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aHoffmeister, Michael$$b10$$eLast author$$udkfz
000153167 773__ $$0PERI:(DE-600)1474822-8$$a10.1002/ijc.32868$$gp. ijc.32868$$n4$$p1018-1026$$tInternational journal of cancer$$v147$$x1097-0215$$y2020
000153167 909CO $$ooai:inrepo02.dkfz.de:153167$$pVDB
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6e02c183f41e45a5867dec393fb4616a$$aDeutsches Krebsforschungszentrum$$b0$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)7d7ee36ed0313bbc4c91bc3df5950107$$aDeutsches Krebsforschungszentrum$$b1$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)bbfe0ebad1e3b608bca2b49d4f86bd09$$aDeutsches Krebsforschungszentrum$$b2$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)9b2a61b2abe4a64ca23b6783b7c4fe63$$aDeutsches Krebsforschungszentrum$$b3$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)c259d6cc99edf5c7bc7ce22c7f87c253$$aDeutsches Krebsforschungszentrum$$b8$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)90d5535ff896e70eed81f4a4f6f22ae2$$aDeutsches Krebsforschungszentrum$$b9$$kDKFZ
000153167 9101_ $$0I:(DE-588b)2036810-0$$6P:(DE-He78)6c5d058b7552d071a7fa4c5e943fff0f$$aDeutsches Krebsforschungszentrum$$b10$$kDKFZ
000153167 9131_ $$0G:(DE-HGF)POF3-313$$1G:(DE-HGF)POF3-310$$2G:(DE-HGF)POF3-300$$3G:(DE-HGF)POF3$$4G:(DE-HGF)POF$$aDE-HGF$$bGesundheit$$lKrebsforschung$$vCancer risk factors and prevention$$x0
000153167 9141_ $$y2020
000153167 915__ $$0StatID:(DE-HGF)0420$$2StatID$$aNationallizenz
000153167 915__ $$0StatID:(DE-HGF)0200$$2StatID$$aDBCoverage$$bSCOPUS
000153167 915__ $$0StatID:(DE-HGF)0300$$2StatID$$aDBCoverage$$bMedline
000153167 915__ $$0StatID:(DE-HGF)0310$$2StatID$$aDBCoverage$$bNCBI Molecular Biology Database
000153167 915__ $$0StatID:(DE-HGF)0100$$2StatID$$aJCR$$bINT J CANCER : 2017
000153167 915__ $$0StatID:(DE-HGF)0199$$2StatID$$aDBCoverage$$bClarivate Analytics Master Journal List
000153167 915__ $$0StatID:(DE-HGF)0110$$2StatID$$aWoS$$bScience Citation Index
000153167 915__ $$0StatID:(DE-HGF)0150$$2StatID$$aDBCoverage$$bWeb of Science Core Collection
000153167 915__ $$0StatID:(DE-HGF)0111$$2StatID$$aWoS$$bScience Citation Index Expanded
000153167 915__ $$0StatID:(DE-HGF)1030$$2StatID$$aDBCoverage$$bCurrent Contents - Life Sciences
000153167 915__ $$0StatID:(DE-HGF)1050$$2StatID$$aDBCoverage$$bBIOSIS Previews
000153167 915__ $$0StatID:(DE-HGF)9905$$2StatID$$aIF >= 5$$bINT J CANCER : 2017
000153167 9202_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153167 9200_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153167 9201_ $$0I:(DE-He78)C070-20160331$$kC070$$lC070 Klinische Epidemiologie und Alternf.$$x0
000153167 9201_ $$0I:(DE-He78)C120-20160331$$kC120$$lPräventive Onkologie$$x1
000153167 9201_ $$0I:(DE-He78)HD01-20160331$$kHD01$$lDKTK HD zentral$$x2
000153167 9201_ $$0I:(DE-He78)C020-20160331$$kC020$$lC020 Epidemiologie von Krebs$$x3
000153167 980__ $$ajournal
000153167 980__ $$aVDB
000153167 980__ $$aI:(DE-He78)C070-20160331
000153167 980__ $$aI:(DE-He78)C120-20160331
000153167 980__ $$aI:(DE-He78)HD01-20160331
000153167 980__ $$aI:(DE-He78)C020-20160331
000153167 980__ $$aUNRESTRICTED